Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers

Clinical Cancer Research

Volumn 13, Issue 17, 2007, Pages 5144-5149

  Hassan, Raffit ^a   Bullock, Susie ^c,f   Premkumar, Ahalya ^b   Kreitman, Robert J ^a   Kindler, Hedy ^d   Willingham, Mark C ^e   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; IMMUNOTOXIN SS1P; MESOTHELIN; PREDNISONE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; SS1(DSFV)PE38;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASCITES; BACKACHE; CANCER PAIN; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLUSHING; HEART MUSCLE ISCHEMIA; HUMAN; HYPERSENSITIVITY REACTION; HYPOALBUMINEMIA; HYPOTENSION; HYPOXIA; LUNG EDEMA; MALE; MESOTHELIOMA; MYALGIA; OVARY CANCER; PANCREAS CANCER; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PLEURA EFFUSION; PLEURAL PAIN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; PRURITUS; RIGOR; SIDE EFFECT; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; VASCULAR DISEASE; VASCULAR LEAK SYNDROME; VOMITING; WEIGHT GAIN; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OVARY TUMOR; PANCREAS TUMOR;

ADULT; AGED; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTOXINS; INJECTIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS;

EID: 34548858453     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0869     Document Type: Article

References (28)

1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996;93:136-40.
2. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.
3. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
4. Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem1994;269:805-8.
5. Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004;279:9190-8.
6. Gubbels JAA, Belisle J, Onda M, et al. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006;5:50-65.
7. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-68.
8. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7.
9. Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005;13:243-7.
10. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001;7:3862-8.
11. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
12. Chang K, Pastan I, Willingham MC. Frequent expression of the tumor antigen CAK1 in squamous cell carcinomas. Int J Cancer 1992;51:548-54.
13. Chowdhury PS, Viner JL, Beers R, Pastan I. Isolation of a high affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A 1998;95:669-74.
14. Chowdhury PS, Pastan I. Improving antibody affinity by mimicking somatic hypermutations in vitro. Nat Biotechnol 1999;17:568-72.
15. Reiter Y, Brinkmann U, Kreitman RJ, Jung SH, Lee B, Pastan I. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochemistry 1994;33:5451-9.
16. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
17. Hassan R, Lerner MR, Benbrook D, et al. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic cultures in vitro. Clin Cancer Res 2002;8:3520-6.
18. Li Q, Verschraegen CF, Mendoza J, Hassan R. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas. Anticancer Res 2004;24:1327-36.
19. Pai LH, Wittes R, Setser A, Willingham MC, Pastan I. Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin. Nat Med 1996;2:350-3.
20. Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005;23:6719-29.
21. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-6.
22. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006;12:447-53.
23. Posey JA, Khazaeli MB, Bookman MA, et al. A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 2002;8:3092-9.
24. Garland L, Gitlitz B, Ebbinghaus S, et al. Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor. J Immunother 2005;28:376-81.
25. Kreitman RJ, Wilson WH, White JD, et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1622-36.
26. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994;271:58-65.
27. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneousT-cell lymphoma. J Clin Oncol 2001;19:376-88.
28. Zhang Y, Xiang L, Hassan R, et al. Synergistic antitumor activity of Taxol and immunotoxin SS1P in tumor-bearing mice. Clin Cancer Res 2006;12:4695-701.